A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,264 (planned)
- Started
- Dec 21, 2023
- Main results expected
- Nov 2027
- Fully finished
- Jan 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)
Measured over: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Part A and Part B: Progression-Free Survival (PFS)
Measured over: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06119581 · record last updated 2026-11-04 · checked 2026-11-09 15:36 UTC